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ABSTRACT
Background Several characteristics of the metabolic 
syndrome, such as obesity and hypertension, have 
emerged as risk factors for a poor clinical outcome 
in COVID-19. However, most reports lack data on the 
metabolic syndrome itself. This study investigated 
prospectively the relationship between respiratory 
deterioration and the presence of metabolic syndrome or 
abdominal adiposity in patients with COVID-19.
Methods A prospective observational cohort study 
analysing patients with respiratory symptoms who 
presented at a local emergency department in the 
Netherlands. The influence of abdominal adiposity—
assessed by an increased waist–hip ratio—and metabolic 
syndrome on respiratory deterioration and the length of 
hospital stay were analysed with multivariable logistic 
regressions and Kaplan- Meier analyses.
Results In total, 166 patients were analysed, of whom 
86 (52%) tested positive for COVID-19. The prevalence 
of metabolic syndrome did not differ between patients 
with COVID-19 with and without the need for intubation 
or level of supportive care (37.5% vs 48.4%, p=0.338). In 
contrast, abdominal adiposity is an independent risk factor 
for respiratory distress in COVID-19, adjusted for metabolic 
syndrome, age, gender and BMI (OR 1.11, 95% CI 1.02 to 
1.20, p=0.014).
Conclusion This study shows that abdominal adiposity, 
and not the presence of metabolic syndrome, is associated 
with clinical deterioration in COVID-19. This prospective 
study provides further insight into the risk stratification of 
patients with COVID-19 based on a simple measurement 
as the waist and hip circumference.
Trial registration number NL8580.
INTRODUCTION
Since the outbreak of COVID-19 
(SARS- CoV-2) in China in the winter of 
2019, the disease has spread rapidly, causing 
a pandemic. Although the vast majority of 
patients has only mild upper airway symp-
toms, a significant proportion of patients 
suffers from clinically relevant respiratory 
distress and requires hospitalisation. Several 
retrospective cohort studies have described 
the characteristics of admitted patients, 
thereby providing insight in the subgroups at 
risk for clinical deterioration. It was observed 
that, among others, obesity, diabetes and 
hypertension were prevalent comorbidities in 
patients hospitalised with COVID-19.1–3 The 
majority of patients suffering from COVID-19 
who were admitted to the intensive care unit 
(ICU) or deceased had at least one of these 
comorbidities.4 5 Moreover, obesity is a signif-
icant independent risk factor for respiratory 
failure in COVID-19,6 as observations in 2009 
influenza A infection reveal.7 An explana-
tion for this observation was suggested to be 
a prolonged viral excretion in patients with 
obesity.8 Surprisingly, despite a high preva-
lence of obesity among patients with hyper-
tension and diabetes,9 most reports lack data 
on the outcome of COVID-19 in patients with 
and without the metabolic syndrome (MetS). 
Recently published research suggests that 
intra- abdominal fat depositions (representing 
abdominal adiposity) on imaging studies are 
associated with an unfavourable outcome in 
COVID-19.10 11
Visceral fat depositions secrete more inflam-
matory cytokines, causing an imbalance in 
the anti- inflammatory and proinflammatory 
adipokines, thereby altering the immune 
Key question
Is the metabolic syndrome and/or abdominal adiposity 
associated with respiratory distress in COVID-19?
Bottom line
 ► In contrast to the metabolic syndrome, it was shown 
that abdominal adiposity, as measured by an in-
creased waist–hip ratio, is strongly associated with 
an unfavourable outcome in COVID-19.
Why read on
 ► In an extensive COVID-19 study, the presence of met-
abolic syndrome and abdominal adiposity measured 
non- invasively by waist and hip circumference, lev-
els of adipocytokine and duration of hospitalisation 
were analysed and related to oxygen demand.
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response. An imbalance in adipokines, resulting in an 
elevated leptin–adiponectin ratio, is related to increasing 
insulin resistance.12 Overexpression of proinflamma-
tory cytokines, such as leptin and interleukin 6 (IL-6), 
causes oxidative stress and endothelial dysfunction.13 
Recent literature showed that the levels of IL-6, which is 
also partly derived from adipose tissue, are elevated in 
patients with COVID-19 with obesity and severe respira-
tory distress admitted to the ICU.14 15 Possibly, this might 
play a role in the described ‘cytokine storm’ in patients 
with COVID-19, thereby making patients with obesity 
susceptible to respiratory failure.
It has been recognised that the association between the 
type of obesity, insulin resistance and COVID-19 should 
be investigated in detail.16 17 In the current study, we inves-
tigated the association between MetS, separate criteria of 
the MetS and severity of disease course in COVID-19 in 
terms of the required level of respiratory support and the 
length of hospital stay. We hypothesised that patients with 
MetS are at risk for an unfavourable course of COVID-19 
within 30 days after presentation at the emergency room 
(ER).
METHODS
Study design and participants
The MASC study (acronym of Metabolic syndrome And 
Severity of COVID-19) is a prospective cohort study, 
conducted from 16 April 2020 until 23 May 2020 at the 
Franciscus Gasthuis & Vlietland, Rotterdam, the Nether-
lands. Consecutive patients, aged ≥18 years, presenting 
with respiratory symptoms or fever suspect for having 
COVID-19, were assessed for inclusion. The presence of 
COVID-19 was confirmed by means of PCR performed 
on patient material obtained by a nasopharyngeal swab 
or serologic tests. Patients presenting with respiratory 
symptoms who repeatedly tested negative on COVID-19 
PCR but positive for SARS- CoV-2 antibodies were consid-
ered positive for COVID-19. Patients with a ‘do not resus-
citate/intubate’ order, patients unable to stand upright 
(due to respiratory distress or pre- existent comorbidi-
ties) or patients without measurements of hip and waist 
circumference were excluded. Patients were followed 
prospectively for 30 days after presentation. By order of 
the local research board, only oral consent but no written 




Unfavourable outcome of disease was defined as being 
admitted to the hospital with requirement of maximum 
respiratory support of 3 L/minute (min) supplemental 
oxygen or more at any time during follow- up, require-
ment of supplemental oxygen by means of high- flow 
nasal cannula intubation or admission to the ICU.
Favourable outcome of disease was defined as being 
discharged from the hospital having required less than 
3 L/min oxygen or no admission to the hospital ward 
at all. Demand for supplemental oxygen was defined 
as having an oxyhaemoglobin saturation below 94% on 
room air.
Secondary outcomes
Length of stay in hospital: measured in days with a 
follow- up time of 30 days after referral to the ER.
Definitions
The presence of MetS was defined as the presence of any 
three of the following five traits, modified after the Adult 
Treatment Panel III criteria18:
 ► Abdominal adiposity, defined as a waist circumfer-
ence ≥102 cm in men and ≥88 cm in women, meas-
ured in the upright position.
 ► Serum triglycerides ≥1.7 mmol/L or treatment with 
lipid- lowering drugs.
 ► Serum high- density lipoprotein cholesterol 
(HDL- C) <1 mmol/L in men and <1.3 mmol/L in 
women.
 ► Drug treatment for elevated blood pressure.
 ► Non- fasting plasma glucose (>7.8 mmol/L) or drug 
treatment for elevated blood glucose.
Anthropometric characteristics: abdominal adiposity 
was assessed by circumferences measurements of waist–
hip ratio as defined according to WHO.19
In order to provide a biochemical explanation for the 
influence of abdominal adiposity, IL-6 and adipocytokine 
(adiponectin and leptin) levels were measured in blood 
samples that were drawn at ER admission.
Data collection
On presentation, baseline characteristics, clinical, labo-
ratory and radiological data were collected prospectively 
following a predefined study protocol. Key data on demo-
graphics, baseline comorbidities and presenting clin-
ical parameters were obtained for all included patients. 
During physical examination at ER presentation, meas-
urements of waist and hip circumference, height and 
weight were obtained and blood was drawn for routine 
medical care and cytokine analyses. Detailed data on 
clinical outcomes, such as supportive care, (duration of) 
admission, ICU admission and survival were registered 
at the end of the 30- day follow- up period. Baseline and 
outcome data were obtained by means of standardised 
data collection forms.
Laboratory measurements were carried out at the 
Department of Clinical Chemistry, Franciscus Gasthuis 
& Vlietland (Rotterdam, the Netherlands) according 
to standard procedures. IL-6, adiponectin and leptin 
heparin plasma concentrations were determined using a 
commercially available ELISA kit (R&D Systems, Minne-
apolis, Minnesota, USA), according to the manufactur-
er’s instructions. The minimum detectable dose (MDD) 
of the ELISA assays was 0.70 pg/mL (IL-6), 0.891 ng/
mL (adiponectin) and 7.8 pg/mL (leptin), respectively. 
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Samples with a concentration lower than the MDD were 
excluded from analyses.
Patient and public involvement section
Patients were not involved in study design, but the 
purpose of the study measurements was explained just 
before measurement. As (abdominal) adiposity and 
MetS (criteria) are both relevant public health issues, 
no patients or public involvement was applicable in 
development of the research questions. Patients were 
politely invited for participation and offered the option 
to decline participation without further explanation or 
the reason why. Patients or public were not involved in 
design/conduct of the study, choice of outcome meas-
ures or recruitment of other patients. Patients/public 
were not involved in publication/dissemination of the 
study results.
Statistical analyses
Baseline data were compared between prespecified 
subgroups based on the presence of COVID-19, MetS 
and favourable or unfavourable outcome. Patients in 
whom data were insufficient to assess the presence of 
MetS (see definition abovementioned) were excluded 
from comparisons between patients with and without 
MetS. Continuous variables were expressed as median 
with IQR and differences between groups compared with 
the Mann- Whitney U test (non- normally distributed vari-
ables) or unpaired t- test (normally distributed variables); 
categorical variables were expressed as number with 
percentages (%) and compared between groups by χ² 
test. A two- sided p of <0.05 was considered a statistically 
significant difference.
Univariable and multivariable binary logistic regression 
analysis were used to study the association between covari-
ates and the course of disease. This was expressed by ORs, 
95% CI and p values. Goodness of model fit was based 
on the model χ2 (p value). In additional analyses, each 
of the five criteria of the MetS, waist–hip ratio and BMI 
is adjusted for age and gender in multivariable logistic 
regression models. Variables with p<0.10 in univariable 
regression were considered as relevant covariates to be 
included in a final multivariable postadjusted regression 
model. Based on an a priori scientific understanding that 
male gender and increasing age are risk factors for an 
unfavourable disease course in COVID-19, these variables 
were included in the multivariable regression regardless 
of the statistical significance in univariable regression. 
To avoid overestimation, not more than five variables 
were included in the final multivariable logistic regres-
sion. Multicollinearity (correlation between waist–hip 
ratio and gender) was checked. Potential confounding 
was evaluated using stratified analysis. A receiver oper-
ating characteristic (ROC) curve was used to validate the 
discriminative ability of the multivariable logistic regres-
sion model. A sample size calculation was up front not 
possible, therefore a post hoc statistical power for the 
multiple regression was calculated.
The association between MetS and length of stay in the 
hospital was analysed by means of univariable and multi-
variable Cox regression. An event was defined as being 
discharged from hospital alive, within the follow- up 
period (30 days after hospital admission). Patients 
who were still admitted and the end of follow- up were 
censored at day 30. Again, multivariable regression was 
performed to adjust for possible imbalances between 
groups. Based on a priori scientific understanding, the 
same variables as in multivariable logistic regression 
were included. Covariates that were statistically signif-
icant and/or closely associated in univariable analysis 
were included in the multivariable model. Kaplan- Meier 
curves were constructed and stratified by presence of 
MetS or increased waist–hip ratio (according to WHO 
criteria19) and unfavourable outcome. Data were anal-
ysed using IBM SPSS Statistics V.26.
RESULTS
Descriptive data
From 506 patients presenting at the ER with suspicion 
of COVID-19, 166 patients were included in the anal-
ysis. Patients unable to stand upright because of respira-
tory distress (n=20), patients with a ‘do not resuscitate/
intubate’ order (n=84), patients with a lack of data 
(no hip and waist circumference measurement) or 
patients unable to stand upright because of comorbid-
ities (n=236) were excluded for analyses (figure 1). Of 
the 166 included patients, 86 (52%) tested positive for 
COVID-19, of whom COVID-19 diagnosis was based on a 
positive PCR in 80 (93%) and a positive antibody test in 
six patients (7%). Due to missing data, presence of MetS 
could not be determined in seven patients, who were 
therefore excluded from comparisons between favour-
able and unfavourable groups.Figure 1 Patient enrolment. ER, emergency room.
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The proportion of patients with MetS was equal 
in patients positive for COVID-19 and negative for 
COVID-19 (table 1, 38.7% vs 41.9%, p=0.984). The 
COVID-19- positive group had a significantly higher 
median BMI (27.8 vs 26.1 kg/m2, p=0.005) and a higher 
proportion of patients with low HDL- C (84.1% vs 36.8%, 
p<0.001) compared with the negative group.
Table 2 shows the clinical parameters of patients with 
(n=33) and without (n=46) MetS. Number of MetS 
criteria divided in favourable and unfavourable outcome 
are shown in online supplemental figure S1. A history 
of cardiovascular disease was more prevalent among 
patients with MetS compared with those without MetS 
(33.3% vs 10.9%, p=0.014). All patients with COVID-19 
and MetS and 89% of patients with COVID-19 without 
MetS were hospitalised (p=0.047). The prevalence of 
MetS did not differ significantly between patients with a 
favourable and unfavourable outcome (37.5% vs 48.4%, 
p=0.338). Among patients with an unfavourable outcome 
of COVID-19 infection, abdominal adiposity was signifi-
cantly more prevalent compared with those with a favour-
able outcome (82.9% vs 58.0%, p=0.015).
Predictive model for unfavourable outcome
Table 3 shows the results from univariable and multivari-
able postadjusted logistic regression, analysing the odds of 
an unfavourable outcome in COVID-19. MetS and all the 
separate criteria of MetS were also analysed in additional 
logistic regressions, adjusted for age and gender, showing 
significant impact on the outcome for both abdominal 
adiposity and also for BMI (online supplemental table S1). 
The final multivariable model shows that the waist–hip 
ratio (OR 1.11, 95% CI 1.02 to 1.20, p=0.014) and BMI (OR 
1.11, 95% CI 1.00 to 1.23, p=0.043) were significantly associ-
ated with an increased risk for an unfavourable outcome of 
COVID-19, when adjusted for MetS, age and gender. MetS 
was not significantly related to an unfavourable outcome in 
univariable and multivariable logistic regressions. Online 
supplemental figure 2 shows that the area under the ROC 
curve was 0.771 (95% CI: 0.664 to 0.878) and post hoc 
statistical power analysis for this model is 0.85.
Length of hospital stay
No patients died during the 30- day follow- up period 
(table 2). Figure 2 shows duration of hospitalisation for 
patients positive for COVID-19, with and without MetS. 
The median (IQR) time until discharge was 6 (3–8) days 
in the MetS group and 5 (3–11) days in the group without 
MetS (log- rank test p=0.921). Figure 3 represents the 
Kaplan- Meier curves of patients with COVID-19 with and 
without abdominal adiposity based on waist–hip ratio. 
Median time until discharge was 4 days in the group 
without abdominal adiposity (IQR 2–8) and 6 days in the 
group with abdominal adiposity (IQR 3–11). There was 
no statistically significant difference between the curves 
(log- rank test p=0.129).
Table 4 shows the univariable and multivariable associ-
ation between patient characteristics and length of stay 
using Cox regression. In univariable Cox regression, 
MetS was not significantly related to length of hospital 
stay (HR=0.98, 95% CI 0.80 to 2.22, p=0.23). Waist–hip 
ratio indicated a prolonged length of hospital stay in the 
univariable Cox regression model (HR=0.98, 95% CI 0.95 
to 0.99, p=0.04). However, it did not show a statistically 
significant effect on length of stay, when adjusted for age 
and gender (p=0.29).
Cytokine measurement
In a subset of patients, the levels of proinflammatory (IL-6, 
leptin) and anti- inflammatory cytokines (adiponectin) 
Table 1 Patient characteristics
COVID-19 negative (n=79) COVID-19 positive (n=86) P value
Male, N (%) 33 (41.8) 40 (46) 0.586
Age, years, median (IQR) 60 (45–67) 56 (47–61.5) 0.267
BMI in kg/m2, median (IQR) 26.1 (23.1–29.3) 27.8 (24.7–32.9) 0.005
Metabolic syndrome, N (%) 26 (41.9) 33 (38.7) 0.984
  Use of antihypertensives, N (%)* 25 (36.2) 22 (25.6) 0.152
  High triglycerides, N (%)* 37 (48.7) 29 (34.5) 0.069
  Low HDL- C, N (%)* 28 (36.8) 69 (84.1) <0.001
  Hyperglycaemia, N (%)* 19 (24.4) 25 (28.7) 0.526
  Abdominal adiposity, N (%)* 46 (60.5) 59 (68.6) 0.283
Waist–hip ratio, median (IQR) 0.96 (0.87–1.02) 0.94 (0.88–1.00) 0.492
History of pulmonary disease, N (%) 35 (44.3) 18 (20.7) 0.001
History of cardiovascular disease, N (%) 18 (22.8) 18 (20.7) 0.744
Median (IQR Q1–Q3) used in variables with non- normal distribution. Statistically significant p- values are bold.
*Metabolic syndrome criterion. Cut- off values: high triglycerides (>1.7 mmol/L), low HDL- C (<1 mmol/L in male, <1.3 mmol/L in female), 
hyperglycaemia ≥7.8 mmol/L and/or drug treatment for elevated blood glucose, abdominal adiposity (male ≥102 cm, female ≥88 cm).
BMI, body mass index; HDL- C, high- density lipoprotein cholesterol; N, numbers.
copyright.











es: first published as 10.1136/bm






van Zelst CM, et al. BMJ Open Resp Res 2020;7:e000792. doi:10.1136/bmjresp-2020-000792 5
Open access
were measured at ER admission and compared between 
groups (table 5, figure 4). Plasma samples for cytokine 
measurement were available from 29 included patients 
(12 COVID-19- positive and 17 COVID-19- negative). 
Baseline characteristics were comparable between these 
two groups table 5Comparison between patients with 
COVID-19 with and without MetS showed that IL-6 was 
lower in patients with COVID-19 with MetS (median 
70.01 vs 30.60 pg/mL, p=0.028). IL-6 was higher in 
patients with COVID-19 with an unfavourable outcome 
than in those without (median 94.7 vs 30.7, p=0.034). 
The leptin–adiponectin ratio was higher among patients 
with COVID-19 with MetS compared with those without 
MetS (ratio 6.6 vs 1.9, p=0.003, table 5. This was not 
observed when comparing the ratio between patients 
with an unfavourable outcome to patients with a favour-
able outcome (p=0.943).
DISCUSSION
This study is the first to investigate the influence of 
abdominal adiposity assessed by the waist–hip circum-
ference, a non- invasive measurement, on COVID-19 
outcome. Abdominal adiposity was significantly associ-
ated with a more severe course of COVID-19, adjusted 
for age, gender and BMI. Similar observations are made 
in recently published studies, analysing the amount of 
intra- abdominal (eg. visceral) fat depositions in patients 
with COVID-19.10 11 Agreeing with the present study, 
these investigations show that abdominal adiposity on 
Table 2 Characteristics of patients positive for COVID-19
Without MetS n=46 MetS n=33 P value
Male, N (%) 23 (50.0) 14 (42.4) 0.506
Age, years, median (IQR) 48.5 (34–60.3) 56.0 (45.3–61.8) 0.107
BMI in kg/m2, median (IQR) 26.5 (23.8–31.4) 30.4 (27.2–35.8) 0.004
MetS, N (%) – – –
  Use of antihypertensives, N (%)* 4 (8.7) 17 (51.5) –
  High triglycerides, N (%)* 2 (4.3) 24 (72.7) –
  Low HDL- C, N (%)* 36 (87.3) 33 (100) –
  Hyperglycaemia, N (%)* 2 (4.3) 19 (57.6) –
  Abdominal adiposity, N (%)* 24 (52.2) 29 (87.9) –
Waist–hip ratio, median (IQR) 0.93 (0.84–0.98) 0.95 (0.90–1.02) 0.034
History of pulmonary disease, N (%) 10 (21.7) 6 (18.2) 0.698
History of cardiovascular disease, N (%) 5 (10.9) 11 (33.3) 0.014
Use of antibiotics, N (%) 19 (41.3) 10 (30.3) 0.274
Deceased (30- day follow- up), N (%) 0 (0) 0 (0) –
Discharged from ER without hospitalisation, N (%) 5 (11) 0 (0) 0.047
Hospitalisation, N (%) 41 (89) 33 (100)
Respiratory support†
  Intubation, N (%) 7 (15) 6 (18) 0.989
  High- flow nasal cannula, N (%) 4 (9) 3 (9)
  Supplemental oxygen 1–6 L/min, N (%) 24 (52) 21 (64)
  6 – – 0.111
  5 1 (2) 2 (6)
  4 0 3 (9)
  3 4 (9) 1 (3)
  2 9 (20) 11 (33)
  1 10 (22) 3 (9)
Hospitalised, without oxygen supply, N (%) 6 (13) 4 (12)
Unfavourable course of disease, N (%) 16 (35) 15 (45) 0.338
Readmission ER related to COVID-19, N (%) 7 (15) 4 (12) 0.658
Sufficient data to diagnose or exclude MetS were missing in seven patients. Median (IQR Q1–Q3) used in variables with non- normal distribution. 
Statistically significant p- values are bold.
*MetS criterion. Cut- off values: high triglycerides (>1.7 mmol/L), low HDL- C (<1 mmol/L in male, <1.3 mmol/L in female), hyperglycaemia ≥7.8 mmol/L 
and/or drug treatment for elevated blood glucose, abdominal adiposity (male ≥102 cm, female ≥88 cm).
†Respiratory support was defined as maximum supplemental oxygen at any given moment during hospitalisation.
BMI, body mass index; ER, emergency room; HDL- C, high- density lipoprotein cholesterol; MetS, metabolic syndrome; N, numbers.
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CT imaging is related to respiratory failure in COVID-
19. However, our results are based on measurement of 
the waist–hip circumference, which is compared with 
abdominal CT scanning, a clinically more feasible and 
non- invasive method to assess abdominal adiposity. Over-
weight (>50%) and obesity (15.9%) are highly prevalent 
in the general Dutch population.20 Patients presenting 
with respiratory symptoms at our centre who tested posi-
tive for COVID-19 had a higher BMI compared with those 
without COVID-19. Given that (abdominal) adiposity is a 
treatable risk factor, in contrast to other risk factors such 
as age and gender, our results underline the relevance 
of this topic in COVID-19 research. In accordance with 
recent literature, the present study also describes a rela-
tionship between BMI and respiratory failure in COVID-
19. But, according to our study, abdominal adiposity 
seems to be a more important risk factor for an unfavour-
able outcome in COVID-19. This is in line with earlier 
reports suggesting that abdominal adiposity is a strong 
predictor for respiratory deterioration in COVID-19 and 
in conditions other than COVID-19.10 11 21–23
The association between MetS and the severity of 
COVID-19 infection was investigated in this study, which 
had never been done before. It was observed that all 
patients with COVID-19 who fulfilled the criteria for MetS 
Table 3 Univariable and multivariable postadjusted logistic regression analyses: association between patient characteristics 
and severity of COVID-19
Covariate
Univariable logistic regression
Final multivariable postadjusted 
logistic regression model
OR (95% CI) P value OR (95% CI) P value
Constant – – 0.000 0.001
Male gender 2.28 (0.95 to 5.48) 0.064 0.90 (0.23 to 3.56) 0.884
Age 1.02 (0.98 to 1.06) 0.288 1.01 (0.96 to 1.06) 0.684
Metabolic syndrome 1.56 (0.63 to 3.90) 0.339 0.70 (0.21 to 2.19) 0.506
Use of antihypertensives* 0.58 (0.21 to 1.63) 0.303 – –
Hypertriglyceridemia* 1.13 (0.45 to 2.83) 0.802 – –
Low HDL- C* 2.63 (0.67 to 10.42) 0.168 – –
Hyperglycaemia* 1.79 (0.70 to 4.58) 0.225 – –
Abdominal adiposity* 3.50 (1.23 to 9.93) 0.019 – –
Waist–hip ratio 1.11 (1.05 to 1.18) 0.001 1.11 (1.02 to 1.20) 0.014
BMI 1.11 (1.02 to 1.21) 0.016 1.11 (1.00 to 1.23) 0.043
Post hoc power – 0.85
*Metabolic syndrome criterion. Cut- off values: high triglycerides (>1.7 mmol/L), low HDL- C (<1 mmol/L in male, <1.3 mmol/L in female), 
hyperglycaemia ≥7.8 mmol/L and/or drug treatment for elevated blood glucose, abdominal adiposity (male ≥102 cm, female ≥88 cm). Statistically 
significant p- values are bold.
BMI, body mass index; HDL- C, high- density lipoprotein cholesterol.
Figure 2 Survival analysis displaying time until discharge 
in patients with COVID-19 compared between patients with 
and without metabolic syndrome (MetS). Median time until 
discharge was 6 days in the MetS group (IQR 3–8) and 5 
days in the group without MetS [(IQR 3–11). Log- rank test 
p value=0.921. Patients who were still admitted and the 
end of the follow- up period were censored at day 30. No 
patients died during follow- up.
Figure 3 Survival analysis displaying time until discharge 
in patients with COVID-19, compared between patients 
with and without abdominal adiposity. Abdominal adiposity 
is defined according to WHO criteria male >0.9 and female 
>0.85 based on WHR. Patients who were still admitted 
and the end of the follow- up period were censored at day 
30. Median time until discharge was 4 days in the group 
without abdominal adiposity (IQR 2–8) and 6 days in the 
group with abdominal adiposity (IQR 3–11). Log- rank test p 
value=0.129. WHR, waist–hip ratio.
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were admitted to the hospital ward, whereas none of the 
patients without the MetS was admitted. However, the 
presented results do not support a relationship between 
MetS and an impaired clinical outcome or duration of 
admission by COVID-19.
This study also investigated the influence of MetS 
and abdominal adiposity on the hospital length of 
stay in patients with COVID-19. Kaplan- Meier analyses 
comparing patients with COVID-19 with or without MetS 
showed no significant differences between the groups. 
The Kaplan- Meier curve comparing patients with and 
without abdominal adiposity showed a trend towards a 
longer duration of hospitalisation in patients with abdom-
inal adiposity, agreeing with the finding that abdominal 
adiposity promotes a more severe course of disease. In 
univariable analysis, abdominal adiposity was associated 
with a longer duration of hospitalisation in COVID-19. 
However, in multivariable Cox regression, there were no 
clinical factors associated with a prolonged duration of 
admission.
Several mechanisms may explain the observed relation 
between abdominal adiposity and respiratory failure. 
First, visceral fat deposits, which are increased in abdom-
inal adiposity, act as a reservoir for viral load promoting 
an inflammatory response.23 24 Augmented visceral fat 
volume is also associated with an impaired viral shed-
ding.8 Second, an imbalance in proinflammatory and 
anti- inflammatory adipokines can cause increased respi-
ratory distress. Levels of IL-6, leptin and adiponectin were 
determined at baseline and compared between groups, 
in order to test the hypothesis that proinflammatory 
adipokines are higher in patients with COVID-19 with 
MetS compared with those without MetS. The presented 
results, although derived from a small sample size, 
support the idea that the leptin–adiponectin ratio was 
elevated in patients with COVID-19 with MetS. No associ-
ation between the leptin–adiponectin ratio on outcome 
in COVID-19 could be demonstrated. In addition, higher 
IL-6 levels were related to an unfavourable outcome. But, 
IL-6 was elevated in patients with COVID-19 irrespective 
of the presence of MetS. This might implicate that IL-6 
levels in low- grade inflammation are negligible in MetS 
compared with the levels measured during COVID-19 
infection. Earlier studies already showed that IL-6 is 
elevated in (severe) COVID-19 and is an independent 
predictor for the need of mechanical ventilation in 
patients with COVID-19.14 25–27
An alternative explanation for the relation between 
abdominal adiposity and respiratory failure, which was 
not further investigated in this study, is that increased 
intra- abdominal pressure due to local fat deposition may 
lead to mechanical obstruction and impaired ventila-
tion of the lower lung regions. In theory, the large waist 
circumference may increase small airway resistance and 
reduce the functional residual capacity (FRC), thereby 
decreasing lung compliance and causing compres-
sion atelectasis.28 This has been demonstrated to be an 
important mechanism of action in other pulmonary 
conditions, such as asthma.29
In contrast to earlier large studies, hypertension or a 
history of cardiovascular disease, which are common 
comorbidities among COVID-19 and well- known risk 
factors for clinical deterioration,1 4 6 30 were not associ-
ated with severe respiratory failure in our cohort. Newly 
discovered hypertension at the ER was not included as 
a criterion of MetS, due to the influence of anxiety and 
stress caused by COVID-19 or hospitalisation. Possibly, 
the use of this definition may have caused a small propor-
tion of patients with hypertension among patients with 
COVID-19 in this study, explaining the discrepancy with 
previous reports.
The present study has a few limitations. First, the cut- 
off value for respiratory distress used in our study was 
a requirement of supplemental oxygen ≥3 L/min. The 
Table 4 Univariable and multivariable Cox regression: association between patient characteristics and time until discharge
Covariate
Univariable Cox regression Multivariable Cox regression
HR (95% CI) P value HR (95% CI) P value
Male gender 0.76 (0.48 to 1.22) 0.25 0.86 (0.45 to 1.61) 0.63
Age (years) 0.99 (0.97 to 1.01) 0.48 0.99 (0.97 to 1.01) 0.68
Metabolic syndrome 0.98 (0.60 to 1.16) 0.93 1.22 (0.69 to 2.15) 0.50
Use of antihypertensives* 1.32 (0.80 to 2.22) 0.23 – –
Hypertriglyceridemia* 1.16 (0.71 to 1.89) 0.55 – –
Low HDL- C* 0.80 (0.40 to 1.61) 0.53 – –
Hyperglycaemic* 0.87 (0.52 to 1.45) 0.59 – –
Abdominal adiposity* 0.77 (0.47 to 1.27) 0.30 – –
Waist–hip ratio 0.98 (0.95 to 0.99) 0.04 0.98 (0.95 to 1.02) 0.29
BMI 0.97 (0.93 to 1.01) 0.12 0.97 (0.92 to 1.01) 0.12
HR <1 related to prolonged length of stay, HR >1 shortened length of stay. −2Log Likelihood 499.14, χ2=7.24, p=0.203. Statistically significant p- 
values are bold.
*Metabolic syndrome criterion. Cut- off values: high triglycerides (>1.7 mmol/L), low HDL- C (<1 mmol/L in male, <1.3 mmol/L in female), 
hyperglycaemia ≥7.8 mmol/L and/or drug treatment for elevated blood glucose, abdominal adiposity (male ≥102 cm, female ≥88 cm).
BMI, body mass index; HDL- C, high- density lipoprotein cholesterol.
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rationale for this cut- off point was based on clinical expe-
rience in our centre. It was observed that the clinical 
condition in patients with COVID-19 often deteriorated 
soon after admission and that oxygen demand quickly 
increased in patients who required oxygen at ≥3 L/
min. A cut- off value of ≥3 L/min to define respiratory 
distress was also used in a study by Demoule et al.31 In 
this analysis, 257 out of 397 patients required intubation, 
thereby underlining the rationale for the applied cut- off 
value. Second, the sample size is limited, foremost in the 
measurement of cytokines, and documentation of clinical 
parameters is incomplete in some cases. However, post 
hoc analysis revealed a power of 0.85 for the presented 
model, meaning acceptable power. Finally, some bias 
in measurement of the waist–hip circumference could 
not be avoided, as they are supposed to be measured in 
upright position. Therefore, patients who were unable 
to stand at admission due to respiratory distress had to 
be excluded from analysis, thereby introducing selec-
tion bias. However, given the small number of patients to 
whom this applied (20 out of 506), the influence on the 
results is expected to be limited.
CONCLUSION
In the present study, MetS did not appear to be of influ-
ence on the clinical outcome in COVID-19. However, the 
results show a clear association between respiratory dete-
rioration in COVID-19 and abdominal adiposity, assessed 
by the easily measurable waist–hip circumference. As 
abdominal adiposity is prevalent worldwide,32 the influ-
ence on clinical outcome in COVID-19 is equally, if 
not more, important than the effect of BMI. Further 
research with bigger sample size, extensive determina-
tion of bioinflammatory markers and lung function data 
(ie, FRC) could help to explain the underlying mecha-
nisms responsible for the association between abdominal 
adiposity and respiratory distress in COVID-19.
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Figure 4 Distribution and comparison of leptin–adiponectin ratio between patients positive for COVID-19 and negative for 
COVID-19 and patients positive for COVID-19 divided in favourable and unfavourable outcome. IL-6, interleukin 6; MetS, 
metabolic syndrome.
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